In vivo, the antitumor efficacy of tepotinib was tested in mice bearing human tumor xenografts, representing various mechanisms of MET activation across multiple indications, including NSCLC and gastric cancer (30, 33, 37, 44). Here, MET is linked to non-small cell lung carcinoma.